Cargando…

Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone

BACKGROUND/AIMS: Opioids cause gastrointestinal (GI) dysmotility, decrease gut secretion, and affect gut sphincters. Symptoms of opioid-induced bowel dysfunction may be alleviated by peripherally acting opioid antagonists like naloxegol, but detailed knowledge on GI effects of this drug is lacking....

Descripción completa

Detalles Bibliográficos
Autores principales:	Olesen, Anne E, Grønlund, Debbie, Mark, Esben B, Krogh, Klaus, Frøkjær, Jens B, Drewes, Asbjørn M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Neurogastroenterology and Motility 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786453/ https://www.ncbi.nlm.nih.gov/pubmed/31587551 http://dx.doi.org/10.5056/jnm18079

Ejemplares similares

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction
por: Poulsen, Jakob Lykke, et al.
Publicado: (2014)

Colonic volume in patients with functional constipation or irritable bowel syndrome determined by magnetic resonance imaging
por: Klinge, Mette Winther, et al.
Publicado: (2022)

A novel MRI‐based three‐dimensional model of stomach volume, surface area, and geometry in response to gastric filling and emptying
por: Bertoli, Davide, et al.
Publicado: (2022)

Acute physiological and electrical accentuation of vagal tone has no effect on pain or gastrointestinal motility in chronic pancreatitis
por: Juel, Jacob, et al.
Publicado: (2017)

Characterization of cortical source generators based on electroencephalography during tonic pain
por: Hansen, Tine Maria, et al.
Publicado: (2017)

Regional gastrointestinal transit times in patients with chronic pancreatitis
por: Larsen, Isabelle M., et al.
Publicado: (2022)

MRI-Based Quantification of Pan-Alimentary Function and Motility in Subjects with Diabetes and Gastrointestinal Symptoms
por: Bertoli, Davide, et al.
Publicado: (2023)

Prediction of opioid dose in cancer pain patients using genetic profiling: not yet an option with support vector machine learning
por: Olesen, Anne Estrup, et al.
Publicado: (2018)

Patient and Disease Characteristics Associate With Sensory Testing Results in Chronic Pancreatitis
por: Kuhlmann, Louise, et al.
Publicado: (2019)

Clinical Course of Medically Managed Patients With Large and Small Duct Chronic Pancreatitis
por: Mahdi, Marco B., et al.
Publicado: (2022)

Quantification of gastric emptying with magnetic resonance imaging in healthy volunteers: A systematic review
por: Bertoli, Davide, et al.
Publicado: (2022)

Cingulate metabolites during pain and morphine treatment as assessed by magnetic resonance spectroscopy
por: Hansen, Tine Maria, et al.
Publicado: (2014)

Cingulate glutamate levels associate with pain in chronic pancreatitis patients
por: Hansen, Tine Maria, et al.
Publicado: (2019)

Central Processing of Gut Pain in Diabetic Patients With Gastrointestinal Symptoms
por: Frøkjær, Jens Brøndum, et al.
Publicado: (2009)

Study protocol for a randomised double-blinded, sham-controlled, prospective, cross-over clinical trial of vagal neuromodulation for pain treatment in patients with chronic pancreatitis
por: Muthulingam, Janusiya Anajan, et al.
Publicado: (2019)

Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham controlled clinical trial
por: Muthulingam, Janusiya Anajan, et al.
Publicado: (2021)

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder
por: Ulteig, Crista, et al.
Publicado: (2022)

Naloxegol and Postoperative Urinary Retention: A Randomized Trial
por: Turan, Alparslan, et al.
Publicado: (2022)

Is Altered Central Pain Processing Related to Disease Stage in Chronic Pancreatitis Patients with Pain? An Exploratory Study
por: Bouwense, Stefan A. W., et al.
Publicado: (2013)

Influence of tapentadol and oxycodone on the spinal cord and brain using electrophysiology: a randomized, placebo‐controlled trial
por: Nedergaard, Rasmus Bach, et al.
Publicado: (2022)

Extragastrointestinal Symptoms and Sensory Responses During Breath Tests Distinguish Patients With Functional Gastrointestinal Disorders
por: Wilder-Smith, Clive H., et al.
Publicado: (2020)

Improved Process for the Preparation of Naloxegol Oxalate, an Opiod Receptor Antagonist
por: Velugula, Siva Rama Kasibabu, et al.
Publicado: (2023)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Rectal Sensitivity in Diabetes Patients with Symptoms of Gastroparesis
por: Søfteland, Eirik, et al.
Publicado: (2014)

Altered Brain Microstructure Assessed by Diffusion Tensor Imaging in Patients With Diabetes and Gastrointestinal Symptoms
por: Frøkjær, Jens Brøndum, et al.
Publicado: (2013)

The Impact of Opioid Treatment on Regional Gastrointestinal Transit
por: Poulsen, Jakob L, et al.
Publicado: (2016)

Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial)
por: Juel, Jacob, et al.
Publicado: (2015)

Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy
por: Klinge, Mette W, et al.
Publicado: (2021)

Naloxegol hydrogen oxalate displaying a hydrogen-bonded layer structure
por: Gelbrich, Thomas, et al.
Publicado: (2018)

Can Naloxegol Therapy Improve Quality of Life in Patients with Advanced Cancer?
por: Ostan, Rita, et al.
Publicado: (2021)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Dietary Intervention Improves Gastrointestinal Symptoms after Treatment of Cancer in the Pelvic Organs
por: Borre, Mette, et al.
Publicado: (2023)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
por: Yoon, Stephanie C, et al.
Publicado: (2017)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t212q2vmk4gh8r9bi8d4t47h1m